Published in Mol Cell Ther on March 24, 2015
Hypoxia-Mimicking Nanofibrous Scaffolds Promote Endogenous Bone Regeneration. ACS Appl Mater Interfaces (2016) 0.75
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica (2004) 5.21
Iron-chelating therapy for transfusional iron overload. N Engl J Med (2011) 3.92
Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med (2005) 3.38
Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet (2003) 3.07
Regulation of cellular iron metabolism. Biochem J (2011) 3.03
Mineralization in ferritin: an efficient means of iron storage. J Struct Biol (1999) 2.69
Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet (2000) 2.66
Stoichiometric and site characteristics of the binding of iron to human transferrin. J Biol Chem (1978) 2.63
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A (2006) 2.36
Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol (2001) 2.36
Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture. Acc Chem Res (2009) 2.32
The Haber-Weiss reaction and mechanisms of toxicity. Toxicology (2000) 2.30
Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol (1978) 2.07
Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med (1998) 2.03
Lactulose, 51Cr-labelled ethylenediaminetetra-acetate, L-rhamnose and polyethyleneglycol 400 [corrected] as probe markers for assessment in vivo of human intestinal permeability. Clin Sci (Lond) (1986) 1.78
Iron chelation with desferrioxamine B in adults with asymptomatic Plasmodium falciparum parasitemia. Blood (1992) 1.53
Role of deferiprone in chelation therapy for transfusional iron overload. Blood (2003) 1.52
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood (2012) 1.49
Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract Res Clin Haematol (2005) 1.46
Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol (2003) 1.46
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood (2003) 1.46
Dendritic polyglycerols for biomedical applications. Adv Mater (2010) 1.38
How I treat transfusional iron overload. Blood (2012) 1.29
The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem (1996) 1.28
Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Br Med J (Clin Res Ed) (1987) 1.28
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? Expert Opin Drug Saf (2013) 1.25
Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag (2007) 1.14
Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood (1998) 1.13
Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology (2007) 1.11
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? Expert Opin Drug Saf (2013) 1.11
Design of iron chelators with therapeutic application. Dalton Trans (2012) 1.06
Objectives and mechanism of iron chelation therapy. Ann N Y Acad Sci (2005) 1.05
Superoxide generation by NADPH-cytochrome P-450 reductase: the effect of iron chelators and the role of superoxide in microsomal lipid peroxidation. Arch Biochem Biophys (1984) 0.98
Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. Drug Metab Dispos (1993) 0.97
The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. Blood (2000) 0.93
Iron binding dendrimers: a novel approach for the treatment of haemochromatosis. J Med Chem (2006) 0.93
Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin Pediatr Neurol (2006) 0.93
The pathophysiology of transfusional iron overload. Hematol Oncol Clin North Am (2014) 0.92
Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers. Proc Natl Acad Sci U S A (1989) 0.92
Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica (2000) 0.90
In vitro chelating, cytotoxicity, and blood compatibility of degradable poly(ethylene glycol)-based macromolecular iron chelators. Biomaterials (2008) 0.90
Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG. Biometals (2009) 0.90
Deferasirox: pharmacokinetics and clinical experience. Expert Opin Drug Metab Toxicol (2011) 0.84
In vivo circulation, clearance, and biodistribution of polyglycerol grafted functional red blood cells. Biomaterials (2012) 0.84
Hydrophobically derivatized hyperbranched polyglycerol as a human serum albumin substitute. Biomaterials (2008) 0.83
Effect of iron loading on transmembrane potential, contraction, and automaticity of rat ventricular muscle cells in culture. J Lab Clin Med (1989) 0.82
Design of long circulating nontoxic dendritic polymers for the removal of iron in vivo. ACS Nano (2013) 0.81
The regulation of iron transport. Biofactors (2013) 0.81
Chelating agents. Chemotherapy (2001) 0.81
Effects of deferasirox on renal function and renal epithelial cell death. Toxicol Lett (2011) 0.81
Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes. Blood (2001) 0.81
Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment. J Pediatr Hematol Oncol (1997) 0.81
Hydroxamic acid-containing hydrogels for nonabsorbed iron chelation therapy: synthesis, characterization, and biological evaluation. Biomacromolecules (2005) 0.81
HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy. Blood (1999) 0.79
Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator. Br J Haematol (2007) 0.79
Evaluation of polymeric hydroxamic acid iron chelators for treatment of iron overload. J Pharmacol Exp Ther (1985) 0.79
Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months. Transfusion (2010) 0.79
Synthesis and iron(III)-chelating properties of novel 3-hydroxypyridin-4-one hexadentate ligand-containing copolymers. Biomacromolecules (2008) 0.77
First report of drug-induced esophagitis by deferasirox. Int J Hematol (2012) 0.76
Liposome entrapped desferrioxamine and iron transporting ionophores: a new approach to iron chelation therapy. Br J Haematol (1979) 0.76
A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity. Ann N Y Acad Sci (1998) 0.76